As learnt from JUFEEL International Group by reporter on April 3rd, the shipping cargo contains 1950 cartons of biologicals worth of 5 million USD will depart from the port of Qingdao today for the second export. The shipping period is approximate 21 days to reach the port of Dar es Salaam, Tanzania, and ETA by the end of April.

　　According to JUFEEL, this batch of PMAS will still be applied for the clinical trial of HIV/AIDS. As early as 2017, JUFEEL International Group has donated the worth of 5.3 million USD of Aloe Polysaccharide Extractive PMAS to National Institute For Medical Research ( NIMR ) in Tanzania. The JUFEEL PMAS has been approved by Tanzania Food & Drugs Authority ( TFDA ), NIMR and its 10 subordinate hospitals has carried out the first phase of clinical trial to treat HIV by JUFEEL PMAS.

　　A total number of 300 HIV patients participated the clinical trial in nearly six months, and the trial revealed that there was an average decrease of 73.6% of viral load in the patients’ blood, moreover, among them, the viral load of 7 patients has reduced to undetectable level.

　　On Sep 12th, the special economic adviser to the president of Tanzania, Mr. IGOGO, visited the headquarters of JUFEEL International Group, and expressed profound gratitude to Professor Zhang Rongxuan, the international patent holder of PMAS technology, as well as the Chairman of board of JUFEEL International Group. Mr. IGOGO came along with the clinical reports from a dozen of hospitals in Tanzania on the HIV/AIDS treatment by JUFEEL PMAS, and again appreciated Professor Zhang for his outstanding dedication to medical and health services in Tanzania.

　　On Jan 3rd, 2019, JUFEEL International Group and PMAS Biotechnology Co., (Tanzania) Ltd entered into agreement in respect of second phase of clinical trial to treat HIV/AIDS by JUFEEL PMAS. Pursuant to this agreement, JUFEEL International Group is to supply NIMR in Tanzania the value of 5.3 million USD of Aloe Polysaccharide Extractive PMAS, also named as supper ZD, and for the second phase of clinical trial. Hopeful, JUFEEL PMAS will be approved to register to National Medical Security System of Tanzania.

　　The original unit or organization provides the information on this platform shall be fully responsible for the content and accuracy of the released information.